Abstract
Objectives: Neoadjuvant chemotherapy is being increasingly used prior to debulking for ovarian serous carcinoma. There can be significant histopathologic alterations, sometimes making the pathologic diagnosis challenging. Methods: A Medline search was performed, and articles describing the histologic changes associated with neoadjuvant chemotherapy, as well as any possible clinical impact, were reviewed. Results: The scope of histopathological changes seen after neoadjuvant chemotherapy for ovarian serous carcinoma, as well as their possible clinical significance is presented. Conclusions: Histopathologic changes include degenerative changes, increased atypia, and alterations that may make pathologic interpretation difficult, particularly if there is a lack of familiarity with these changes and lack of available clinical history. More study is needed to assess whether there is any prognostic significance to these alterations.